I shall discuss briefly, first of all, about fou~types of experimental design in which drugs are used in relation to disorders of affect. These types of design have been discussed more fully by Roger Russell (1960) .
( 1) In the first design, the drugs are used as the independent variable-the disordered affect being the dependent variable. Much clinical research falls into this category. The question usually is: Does drug A produce a change in disordered affect B? Change is measured by such things as rating of behaviour, improvement ratings, and so on. In this type of study, the emphasis is on the value or understanding of the drug rather than on the understanding of the disordered affect. The drug is the object of study rather than a tool. (~) . In t~e second design, the drug agam IS the independent variable but the dependen~variable is usually more specific than in the first design. Subjective changes may be measured, as in the work of Beecher (1952 Beecher ( , 1955 , Laties (1959) , Clyde ( 1960), and Gottschalk ( 1960) . Such studies face a number of problems. Some workers feel that only well-trained subjects can be used (Gottschalk et al 1956) , and there is the problem of the lack of significant correlations between subjective states and objective effects (Kornetsky, Humphries and Evarts [1957] , Kornetsky [1960] ).
More generally we must note that, though the subjective changes may be known to be related to the disordered affect, such studies tell us more about the drug than about the disorder of affect unl~ss, ?f course, the mechanism of drug actIon IS already known. If it is known "The work reported in this paper was supported by a grant from Wallace Laboratories, New Jersey. lDepartment of Public Health, Mental Health Clinic Regina General Hospital, Regina, Saskatchewan. ' that the drug produces certain biochemical changes, then the finding that the drug produces changes in subjective processes related to the disordered affect may give us some knowledge of the biochemical basis of the disordered affect. The drug in this case is a tool. But it is rare that the mechanism of action of a drug is well established and, as I shall show later, drugs may be used as tools before their action is known-indeed .
., tudles can be designed in which the drug IS both a tool and object of study.
( 3) Drugs such as LSD may be used to produce model behaviour patterns. Here the drug is being used as a tool. The problem is in producing models that are essentially like the original conditions and deciding when such essential similarity exists. The approach has been described in detail by Wikler (1956) .
(4) Drugs may be used to test particular hypotheses relating disorder of affect as an intermediate condition or behaviour and other aspects of behaviour. For instance, if it is found that anxiety produced by stress has a certain effect on a psychological test, a drug that has been shown to have an effect on anxiety may be used to alter the anxious state and thus. furt?er the understanding of the relationship between the disordered affect and performance on the psychological test.
As examples of such an approach, we ca.n look at the work of Holliday and Dille (1958) . Using a pointer pursuit apparatus, they punished the subject on some trials when he was off target. This punishment produced poorer performance on the unpunished trials, except when the subject was under the effects of 800 mg. meprobamate. The drug apparently reduced the anxiety engendered by the anticipation of punishment. Similar improvement in performance with meprobamate on a simple attention test under the threat of stress conditions was found by Uhr, Platz and Miller (1960) . Similar effects of nitrous oxide on anxiety produced by stress have been reported by Russell and Steinberg (1955) .
In this kind of design, the drug certainly is being used as a tool. But I think a further worthwhile refinement to such a design is the manipulation of the anxiety or disordered affect itself, so that the interaction between the disordered affect and the drug can be investigated. In the above kind of design, a control anxiousgroup may be used-control in that they are given a placebo or no drug at all. But it is not usual for a non-anxious group also to be used.
II. Individual Differences in Reactions
to Drugs I hope to be able to demonstrate that the manipulation of level of disordered affect in a factorial type design is a promising method of approach; that generally the manipulation of differences between subjects is worthwhile, and perhaps even necessary, as is indicated by the numerous reports of individual differences in reaction to drugs.
Restricting ourselves to studies concerned with disorders of affect, Von Felsinger, Lasanga and Beecher (1955) found that the predominant reaction to amphetamine was euphoria but four of the twenty subjects experienced dysphoria and five felt sedated. They found that the seven subjects who showed marked stimulation were the most responsive, expansive and well adjusted, whereas those responding with dysphoria were conspicuously lacking in appropriate motivation towards their work. Those sedated had marked depressive tendencies. DiMascio and Klerman (1960) reported that individuals whose personality was organized around active mastery of the environment found sedative drug actions ego-threatening and therefore reacted with denial and negation of effects. In contrast, passive anxious individuals ac-cepted more readily sedative drug actions and experienced great reduction of anxiety and tension.
Warshaw's finding, reported by Clyde (1960) , that neurotics could feel the difference between a placebo and 400 mg. of meprobamate, but that emotionally stable subjects could not, also indicates the importance of individual differences.
The literature on individual differences in reactions to drugs has been reviewed recently by Uhr (1960) .
III. Level of Motivation
Another aspect of the experiment which can be controlled in the factorial type design is the attitude of the subject. There is some evidence that the level of motivation is an important variable in reaction to drugs. Hill, Belleville and Wikler (1957) found that under conditions of low incentive, the subjects being morphine addicts and the incentive being morphine, phenobarbital increased reaction time, whereas under high incentive conditions it decreased reaction time.
IV. Introduction to Experiment
In the hope of demonstrating the value of the factorial method in drug studies, an experiment was designed in which the drug administered, the anxiety level of the subject, and the level of the subject's motivation were the variables manipulated.
. H. M. Brachman of the Regina Psychological Laboratory in a recent study has found that 40 neurotic subjects, chosen on the basis of their extreme scores on the Junior Maudsley Personality Inventory (Furneaux and Gibson, 1961) administered to 514 children between the ages of 14 and 16, were less persistent than 40 normal children on a mental persistence task. In view of the high correlation between the Taylor Manifest Anxiety Scale (Taylor, 1953) and the Neuroticism Scale of the M.P.!. (Bendig, 1960) , it seemed likely that the degree of the subject's anxiety was an important determinant of his persistence. It was decided therefore to investigate the rela-tionship between anxiety as measured by the Taylor scale and persistence, and to investigate also the effects of the SUbject's level of motivation and the tranquilizer, meprobamate, on persistence.
The effects of anxiety on performance, as measured by the Taylor Scale, has been studied quite extensively by Sarason, Mandler and Craighill (1952) , Mandler and Sarason (1952) , Matarazzo, Ulett, Guze and Saslow (1954) , Matarazzo, Ulett and Saslow (1955) , Matarazzo and Phillips (1955) , Davidson, Andrews and Ross (1956) , Katchmar, Ross and Andrews (1958) , Taylor (1958) , Kalish, Garmezy, Rodnick and Bleke (1958) , Nicholson (1958) , Wiener (1959) , Sarason and Palola (1960) and provides us with what I feel is an important link between the general field of psychology and psychopharmacology. Of particular relevance to this study is the finding of Mandler and Sarason (1952) that the mean time scores on the Kohs Block Design of a low anxiety group were better than those of the high anxiety group. On the basis of this finding, the Kohs Block Design was included in the study. We have already suggested, above, the possible importance of controlling the subject's level of motivation. Another reason for introducing it as a variable in this study was that it forged another link with general psychology in that a number of studies have reported a significant interaction between anxiety and level of motivation. Sarason (1956 Sarason ( , 1957 Sarason ( , 1959 found that motivational instructions were detrimental for high anxious groups on the Taylor Anxiety Scale and facilitating for low and middle anxious groups. Similar results have been reported by Katchmar, Ross and Andrews (1958) and Nicholson (1958) .
V. Method of Experiment
The Taylor Anxiety Scale was administered to 240 female student and graduate nurses. The twenty subjects with the highest scores (anxious group) and the twenty with the lowest scores (non-anxious group) were selected. Each of these groups was divided randomly into two SUb-groups of 10 subjects. One subgroup was given 800 mg. meprobamate in tablet form 1Yz hours before testing and the other group was given identicallyappearing placebo tablets 1Yz hours before testing. Neither the subject nor the experimenter knew whether the tablets were meprobamate or placebo and the experimenter did not know to which group the subject belonged, anxious or non-anxious. The two SUb-groups of ten subjects were further split randomly into two SUb-groups of five. One of the subgroups received ego-involving instructions at the beginning of the testing session-"These tests have been shown to be good measures of the efficiency of a person's intelligence. We have found that people who do well in them are generally successful in life". The other SUb-group received task-involving instructions-"These tests have been specifically designed for this study. They are not intelligence tests. Weare more interested in finding out something about the tests themselves than about a person's intelligence".
All the subjects were first of all shown how to do design 1 of the Wechsler-Bellevue Block Design Test (Wechsler, 1944) . The subject was then presented with Design 8 and told to do it as quickly as possible, and the time needed for completion was recorded.
The subject was then given an unsolvable Magic Number Square task, as used by MacArthur (1955) in his study of persistence. The subject was told she could spend as much time as she wished on the task. After 5 minutes, and thereafter at 10 minute intervals, she was given the opportunity to quit and try another kind of Magic Square problem. The time elapsing before the subject quit was taken as a measure of her persistence.
VI. Results
An analysis of variance was done on the data for both the Kohs Block Design and the Mental Persistence Task. Looking at the Kohs Blocks first, it was found that the subjects under task-involved conditions completed the design more quickly than those under ego-involved conditions. The means were 1.57 min. and 2.29 min. respectively. In· line with Mandler and Sarason's findings, this suggests that the ego-involving instructions aroused anxiety which interfered with performance. There was not an overall effect of anxiety on this task and this was due to the significant interaction between the anxiety level of the subject and the drug administered. Under Placebo conditions, the anxious subjects take longer (2.11 min.) to complete the design than the nonanxious subjects (1.81 rnin.). But, when we compare the groups under meprobamate conditions, the anxious group takes 1.45 min.-an improvement of 31 % over the placebo group, whereas the nonanxious group under meprobamate takes 2.36 min., a loss of 30% when compared with the non-anxious group under placebo conditions.
In the case of mental persistence also, it was found that the anxiety/drug interaction was significant. The anxious subjects under placebo conditions had a mean persistence of 16.31 min., and under meprobamate conditions 31.37 min. -an increase in persistence of 92%. The nonanxious subjects under placebo conditions had a mean persistence of 22.43 min., and under meprobamate conditions 19.89 rnin., a loss in persistence of 11%. Level of motivation did not contribute significantly to the variance.
VII. Discussion and Conclusion
We must now answer the questionhas this experiment told us any more about anxiety than experiments investigating the effects of drugs on anxiety produced by stress? There is, of course, one point that we can make immediately and that is that in this experiment anxiety has been treated as a personality characteristic of the individual and not anxiety of a temporary situational nature (Calvin, McGuigan, Tyrrell and Soyars [1956] have discussed this). And this may be considered more relevant to the problem of disordered affect in the psychiatric sense.
But I think there is a more important point. We found that meprobamate reduced the time for completion of the block design in the anxious subject-this could presumably have been found in a study where anxiety was produced by stress. But we also found that the drug increased the time for completion in nonanxious subjects. This finding we can now use to test the adequacy of two theories that have been formulated to account for the effects of anxiety on performance. We shall discuss the theories briefly. They have been examined more thoroughly elsewhere (Costello 1962) .
In the Associative Theory , Sarason, Mandler and Craighill [1952] , and Child [1954] ) anxiety is a learned drive, which is a function of anxiety reactions previously learned as responses to stimuli presented in testing situations, etc. This anxiety drive primarily elicits responses that tend to reduce the drive and which in some cases may be task irrelevant and interfere with performance. Performance, according to the theory, would appear to be a function of the ratio between task relevant responses and task irrelevant responses, and high-anxious subjects have more task irrelevant responses than lowanxious subjects. It would seem then that meprobamate by reducing anxiety should have reduced task irrelevant responses in both the anxious and the non-anxious groups, thus resulting in improvement in performance for both groups. But, as we have seen above, this did not happen..
The other theory emphasizes the drive aspect of anxiety (Taylor and Spence [1952] ). Taylor (1956) gives two conditions under which high drives may reduce the level of correct performance:
(1) if the strongest response to a stimulus is not the correct one, or (2) if the correct response is strongest but competing responses, which are below threshold with low drive, are moved above threshold by increasing drive. Whatever the important condition, in our study it would seem clear that reducing the anxiety (drive) by administering meprobamate should have improved performance for both the anxious and the nonanxious group.
Both the current theories then would appear to be inadequate in accounting for the results with the Kohs Blocks. The results seem to fit in better with the Yerkes Dodson Law, discussed in detail by Broadhurst (1959) , which would predict that performance would be poor at extreme ends -anxious subjects under placebos and non-anxious under meprobamate -and best near the middleanxious subjects under meprobamate and non-anxious under placebo. This law would also account for the results in the case of the Persistence Task better than the other theories, which are concerned with the quality of performance and not broad enough to account for aspects such as the persistence of performance.
It will be noticed that I have discussed solely anxiety. My reason for the neglect of depression is that, though some work has been done on the effects of drugs on depressive states (Turner and Carl [1939] ), much less work has been done on depression in the general field of psychology. This, in turn, has perhaps been due to the lack of a scale of depression similar to the Manifest Anxiety Scale. And it is due to the lack of a scale of motivation that, despite the title, I have not been able to contribute much data on disordered motivation. It is hoped to develop such scales so that the depression and motivation variables can be introduced into factorial designs similar to the one described above. It will then be that we will be in a position not only to use drugs in the study of anxiety and of depression but also in the study of the interaction or coexistence of these two disordered affects. I. Am. Med. Assoc. ist, 1113 -1119 Furneaux, W. D. and Gibson, H. B. A children's personality inventory designed to measure neuroticism and extraversion. Brit. J. Educ. Psycbol. 1961, in press. Gottschalk, L. A. et al. Explorations in testing drugs affecting physical and mental activity.
t. Amer. Med. Assoc., 1956 , 161, 1054 Motivational determinants in modification of behaviour by morphine and pentobarbital. AMA Arch, Neurol. Psychiat., 1957,77,28-35 . Hill, W. F. Comments on Taylor's "drive theory and manifest anxiety". Psychol. Bull., 1957, 54, 490-493. Resume Si l' on passe en revue les differentes etudes experimentales dans lesquelles la chirniotherapie est utilisee pour etudier les troubles des affects, on constate que l'etude factorielle doit se reveler profi- DR. O'REILLY: Since Dr. Sourkes has been working in this field of adrenaline and noradrenaline, I want to ask about the hypothesis of Dr. A. Hoffer which has caused, as far as I can see, a terrific amount of controversy. His hypothesis is that adrenaline is broken into adrenochrome and then goes into adrenolutin, and he makes the hypothesis that adrenaline is a cause of schizophrenia and adrenolutin is a cause of chronic schizophrenia.
In a recent article in the journal, Archives of General Psychiatry, I think Altshule did say he found some adrenolutin in urine but lately they appear to have found leuconoradrenochrome, which might fit in. But I would like comments on this because this states, "Biochemical changes in expression of emotion", just to line the thing up.
DR. T. L. SOURKES: This theory, or hypothesis, has been written up innumerable times, and almost every time somewhat differently. I think that two things have to be distinguished in presenting a hypothesis: One is that in setting up a hypothesis its terms must hang together. The second is that it must correspond to some facts.
For many years the hypothesis more or less hung together and many of us were prepared to wait for some evidence. After a "method" for measuring adreno-chrome was published by Payza and Mahon, from Dr. Hoffer's laboratory, three groups tried to use it, in the United States, Canada, and Denmark, and they have uniformly found the adrenochrome measurement to be due to an artefact. In addition to this, a group at the National Institute of Mental Health developed another procedure. This method was adequate to measure even smaller amounts of adrenochrome in plasma than Hoffer had been claiming, but they could not detect any.
The only other thing I would like to point out is that there may be controversy, but it is only on one side. From the point of view of biochemists there are no facts, so I do not like to use the word "controversy": it is just something that remains unproven. There may be adrenochrome; there may be noradrenochrome and adrenolutin. Some outstanding chemical work on these compounds has emerged from the Saskatchewan project, but whether these things play any role in physiology or biochemistry is still not known.
DR. G. LING: I would like to support the comments that Dr. Sourkes has just made. Further, several investigators, using fluorimetric procedures, have failed to confirm the presence of adrenochrome in the plasma of either normal or schizophrenic patients.
